All In Biotech

Drug Trial Radar · NCT06101342

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 181 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

181

Actual

Start

Dec 13, 2023

Primary completion

Jul 27, 2026

Study completion Jan 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
HIV Prevention Trials Network; National Institute on Drug Abuse (NIDA); National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Oct 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US). The primary objectives of this study are to characterize the pharmacokinetics (PK) of LEN and to evaluate the safety of LEN and F/TDF for PrEP in US PWID.

Conditions

  • Pre-Exposure Prophylaxis of HIV Infection

Interventions

  • Lenacapavir InjectionDrug

    Administered subcutaneously

  • Lenacapavir TabletDrug

    Administered orally

  • Emtricitabine/tenofovir disoproxil fumarate (F/TDF)Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN): LEN Plasma concentration at the End of the Dosing Interval (Week 26)Time frame: Week 26
  2. PK Parameter: Ctrough for LEN: LEN Plasma concentration at the End of the Dosing Interval (Week 52)Time frame: Week 52
  3. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: First dose date up to 30 days post last dose at Week 52
  4. Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory Abnormalities with LEN and F/TDFTime frame: First dose date up to 30 days post last dose at Week 52

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Vine Street Clinic

    Los Angeles, California

  • UCSD AntiViral Research Center (AVRC)

    San Diego, California

  • University of Miami - Converge Miami Building

    Miami, Florida

  • Johns Hopkins Medicine Institute for Clinical and Translational Research, Clinical Research

    Baltimore, Maryland

  • Rutgers New Jersey Medical School, Department of Medicine

    Newark, New Jersey

  • ICAP at Columbia University- Bronx Prevention Center

    The Bronx, New York

  • University of Pennsylvania, Division of Infectious Diseases Penn Prevention Research Unit

    Philadelphia, Pennsylvania

  • Houston AIDS Research Team CRS

    Houston, Texas

  • West Virginia University

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.